SEC Form 4 · accession 0001193125-26-306072

Cardiff Oncology, Inc. · CRDF

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jul 14, 2026

Accepted (ET)

Jul 16, 2026 · 4:01 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001213037

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 14, 2026	P	34,364	$1.455	A	59,067	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock Purchase Warrant^F1,F2	$1.33	Jul 14, 2026	P	34,364	A	—	—	Common Stock	34,364	34,364	D

F1Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.
F2The term of exercise is equal to five and one-half years after the Initial Exercise Date.